X-linked Adrenoleukodystrophy Pipeline Therapeutics Assessment Report 2024 (Updated)

DelveInsight's, "X-Linked Adrenoleukodystrophy Pipeline Insight, 2024," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in X-Linked Adrenoleukodystrophy (X-ALD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in X-linked adrenoleukodystrophy Research. Learn more about our innovative pipeline today! @ X-linked adrenoleukodystrophy Pipeline Outlook- https://www.delveinsight.com/sample-request/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the X-linked adrenoleukodystrophy Pipeline Report
• DelveInsight's X-linked adrenoleukodystrophy pipeline report depicts a robust space with 3+ active players working to develop 3+ pipeline therapies for X-linked adrenoleukodystrophy treatment.
• The leading X-linked adrenoleukodystrophy Companies such as Minoryx Therapeutics, Viking Therapeutics, Poxel, Orpheris, Applied Genetic Technologies Corporation, NEURALGENE, and others.
• Promising X-linked adrenoleukodystrophy Therapies such as Leriglitazone, SBT101, MIN-102, PXL770, PXL065m and others.

Stay informed about the cutting-edge advancements in X-linked Adrenoleukodystrophy treatments. Download for updates and be a part of the revolution in care @ X-linked Adrenoleukodystrophy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

X-linked Adrenoleukodystrophy Emerging Drugs Profile

• Leriglitazone : Minoryx Therapeutics
Leriglitazone (MIN-102) is a novel, orally bioavailable and selective PPAR gamma agonist with a potential best-in-class profile indicated for CNS diseases. It is one of the several metabolites of pioglitazone and has a demonstrated sufficient brain penetration and favorable safety profile in humans, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. It showed robust preclinical proof-of-concept in animal models of multiple diseases by modulating pathways leading to mitochondrial dysfunction, oxidative stress, neuroinflammation, demyelination and axonal degeneration. The drug is currently in Phase2/3 stage of development for the treatment of Adrenoleukodystrophy.

• PXL770: Poxel
PXL770 is a novel drug candidate that directly activates adenosine monophosphate-activated protein kinase (AMPK). AMPK is a central regulator of multiple metabolic pathways leading to the control of multiple metabolic pathways and reduced inflammation. The rationale for considering AMPK activators in ALD is based on several published findings that show links between AMPK and disease in both animals and humans. PXL770 was evaluated in both the in vitro and in vivo ALD models . PXL770 suppressed elevated VLCFA levels in patient derived cells with an associated increase in expression of the compensatory ABCD2 transporter. PXL770 treatment of ABCD1 null mice also suppressed elevated VLCFA in spinal cord - and in brain and plasma.

• PLX065 : Poxel
PXL065 offers a new approach for the treatment of ALD. PXL065 is the R-stereoisomer (deuterium-modified single R-isomer) of pioglitazone and its parent molecule has been marketed since 1999 for the treatment of type 2 diabetes. Published literature provides a potential rationale for considering D-TZDs in ALD. Firstly, pioglitazone has demonstrated strong efficacy in the classical ALD model, the ABCD1 null mouse; in addition, pioglitazone has been shown to confer neuroprotection in other contexts. Also, a key non-genomic mechanisms modulated by pioglitazone and PXL065 (and other D-TZDs) - the mitochondrial pyruvate carrier - MPC - is also implicated as a target for neurodegeneration.

• OP101 : Orpheris
OP-101 is a new chemical entity consisting of N-acetyl cysteine (NAC) covalently coupled to a metabolically- stable inactive dendrimer. Studies in several small and large pre-clinical models have demonstrated the selective endocytosis uptake of OP-101 by activated microglia/ and astrocytes upon intravenous administration, localizing only in brain regions where there is with neuroinflammation-induced BBB impairment of the blood brain barrier. OP-101 releases NAC intracellularly in activated microglia and astrocytes, which then acts to reduce the attenuating oxidative stress and inflammation, in these cells and leads producing to significant improvements in neurobehavioral outcomes in the preclinical models, unlike the free drug. Macrophages isolated from ccALD patients and stimulated with VLCFA have significantly reduced cytokine expression and glutamate secretion with increased glutathione levels, when treated ex vivo with OP-101. Pilot toxicity studies in juvenile rats show that no toxicity of OP-101 is safe at doses as high as even at 1000 mg/kg IV QOD.

Learn more about X-linked Adrenoleukodystrophy Drugs opportunities in our groundbreaking X-linked Adrenoleukodystrophy Research and development projects @ X-linked Adrenoleukodystrophy Unmet Needs- https://www.delveinsight.com/sample-request/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

X-linked Adrenoleukodystrophy Companies
Minoryx Therapeutics, Viking Therapeutics, Poxel, Orpheris, Applied Genetic Technologies Corporation, NEURALGENE, and others

X linked Adrenoleukodystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

X-linked Adrenoleukodystrophy Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Discover the latest advancements in X-linked Adrenoleukodystrophy Treatment by visiting our website. Stay informed about how we're transforming the future of disease @ X-linked Adrenoleukodystrophy Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the X-linked Adrenoleukodystrophy Pipeline Report
• Coverage- Global
• X-linked Adrenoleukodystrophy Companies- Minoryx Therapeutics, Viking Therapeutics, Poxel, Orpheris, Applied Genetic Technologies Corporation, NEURALGENE, and others.
• X-linked adrenoleukodystrophy Therapies- Leriglitazone, SBT101, MIN-102, PXL770, PXL065m and others.
• X-linked Adrenoleukodystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• X-linked Adrenoleukodystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of X-linked Adrenoleukodystrophy Pipeline on our website @ X-linked Adrenoleukodystrophy Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/x-linked-adrenoleukodystrophy-x-ald-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. X linked Adrenoleukodystrophy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. X linked Adrenoleukodystrophy- DelveInsight's Analytical Perspective
7. Late Stage Products (PhaseII/ III)
8. Leriglitazone : Minoryx Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. PXL770: Poxel
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. OP101: Orpheris
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. X linked Adrenoleukodystrophy Key Companies
21. X linked Adrenoleukodystrophy Key Products
22. X linked Adrenoleukodystrophy- Unmet Needs
23. X linked Adrenoleukodystrophy- Market Drivers and Barriers
24. X linked Adrenoleukodystrophy- Future Perspectives and Conclusion
25. X linked Adrenoleukodystrophy Analyst Views
26. X linked Adrenoleukodystrophy Key Companies
27. Appendix

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.